Fundraising FoxVida Ventures — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US
C. Alexander Kamb(Director)inJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)in
Board seatHelen S. Kim· per SEC Form D
Co-investorsCasdin CapitalMana VenturesNextech InvestThe Column GroupSamsara BioCapital
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatStefan Vitorovic· per SEC Form D
Co-investorsAtlas VentureHatteras Venture PartnersLightstone VenturesPivotal Life SciencesLongwood Fund
Affini-T Therapeutics develops TCR-based immunotherapies aimed at treating solid tumors, using two complementary therapeutic modalities.
BiotechHealthtechLongevity
Co-investorsAgent CapitalJacket River Capital PartnersOlive Tree CapitalService Provider CapitalFred Hutchinson Cancer Research CenterHumboldt+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.